BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

679 related articles for article (PubMed ID: 10720029)

  • 1. Normal ovulatory women with polycystic ovaries have hyperandrogenic pituitary-ovarian responses to gonadotropin-releasing hormone-agonist testing.
    Chang PL; Lindheim SR; Lowre C; Ferin M; Gonzalez F; Berglund L; Carmina E; Sauer MV; Lobo RA
    J Clin Endocrinol Metab; 2000 Mar; 85(3):995-1000. PubMed ID: 10720029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ovarian 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone (GnRH) agonist challenge in women with polycystic ovary syndrome is not mediated by luteinizing hormone hypersecretion: evidence from GnRH agonist and human chorionic gonadotropin stimulation testing.
    Ibañez L; Hall JE; Potau N; Carrascosa A; Prat N; Taylor AE
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4103-7. PubMed ID: 8923867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endocrine abnormalities in ovulatory women with polycystic ovaries on ultrasound.
    Carmina E; Wong L; Chang L; Paulson RJ; Sauer MV; Stanczyk FZ; Lobo RA
    Hum Reprod; 1997 May; 12(5):905-9. PubMed ID: 9194637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 17-hydroxyprogesterone responses to gonadotropin-releasing hormone disclose distinct phenotypes of functional ovarian hyperandrogenism and polycystic ovary syndrome.
    Pasquali R; Patton L; Pocognoli P; Cognigni GE; Gambineri A
    J Clin Endocrinol Metab; 2007 Nov; 92(11):4208-17. PubMed ID: 17785360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific factors predict the response to pulsatile gonadotropin-releasing hormone therapy in polycystic ovarian syndrome.
    Gill S; Taylor AE; Martin KA; Welt CK; Adams JM; Hall JE
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2428-36. PubMed ID: 11397835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gonadotrophin and gonadal steroid response to a single dose of a long-acting agonist of gonadotrophin-releasing hormone in ovulatory and anovulatory women with polycystic ovary syndrome.
    White D; Leigh A; Wilson C; Donaldson A; Franks S
    Clin Endocrinol (Oxf); 1995 May; 42(5):475-81. PubMed ID: 7621565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Source localization of androgen excess in adolescent girls.
    Ibáñez L; Potau N; Zampolli M; Prat N; Gussinyé M; Saenger P; Vicens-Calvet E; Carrascosa A
    J Clin Endocrinol Metab; 1994 Dec; 79(6):1778-84. PubMed ID: 7989484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperandrogenism in women with polycystic ovary syndrome persists after menopause.
    Markopoulos MC; Rizos D; Valsamakis G; Deligeoroglou E; Grigoriou O; Chrousos GP; Creatsas G; Mastorakos G
    J Clin Endocrinol Metab; 2011 Mar; 96(3):623-31. PubMed ID: 21177795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.
    Moghetti P; Castello R; Negri C; Tosi F; Perrone F; Caputo M; Zanolin E; Muggeo M
    J Clin Endocrinol Metab; 2000 Jan; 85(1):139-46. PubMed ID: 10634377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polycystic ovarian morphology with regular ovulatory cycles: insights into the pathophysiology of polycystic ovarian syndrome.
    Adams JM; Taylor AE; Crowley WF; Hall JE
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4343-50. PubMed ID: 15356031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of hormonal response to the GnRH agonist leuprolide in brothers of women with polycystic ovary syndrome: a pilot study.
    Petermann TS; Cartes A; Maliqueo M; Vantman D; Gutiérrez C; Toloza H; Echiburú B; Recabarren SE
    Hum Reprod; 2004 Dec; 19(12):2742-7. PubMed ID: 15358722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Follicle luteinization in hyperandrogenic follicles of polycystic ovary syndrome patients undergoing gonadotropin therapy for in vitro fertilization.
    Foong SC; Abbott DH; Zschunke MA; Lesnick TG; Phy JL; Dumesic DA
    J Clin Endocrinol Metab; 2006 Jun; 91(6):2327-33. PubMed ID: 16551732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pituitary function is altered during the same cycle in women with polycystic ovary syndrome treated with continuous or cyclic oral contraceptives or a gonadotropin-releasing hormone agonist.
    Ruchhoft EA; Elkind-Hirsch KE; Malinak R
    Fertil Steril; 1996 Jul; 66(1):54-60. PubMed ID: 8752611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inappropriate gonadotropin secretion in polycystic ovary syndrome: influence of adiposity.
    Arroyo A; Laughlin GA; Morales AJ; Yen SS
    J Clin Endocrinol Metab; 1997 Nov; 82(11):3728-33. PubMed ID: 9360532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adrenal dynamic responses to physiologic and pharmacologic adrenocorticotropic hormone stimulation before and after ovarian steroid modulation in women with polycystic ovary syndrome.
    Gonzalez F; Chang L; Horab T; Stanczyk FZ; Crickard K; Lobo RA
    Fertil Steril; 1999 Mar; 71(3):439-44. PubMed ID: 10065779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovulation after glucocorticoid suppression of adrenal androgens in the polycystic ovary syndrome is not predicted by the basal dehydroepiandrosterone sulfate level.
    Azziz R; Black VY; Knochenhauer ES; Hines GA; Boots LR
    J Clin Endocrinol Metab; 1999 Mar; 84(3):946-50. PubMed ID: 10084576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters.
    Carmina E; Chu MC; Longo RA; Rini GB; Lobo RA
    J Clin Endocrinol Metab; 2005 May; 90(5):2545-9. PubMed ID: 15728203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polycystic ovaries in Hirsute women with normal menses.
    Carmina E; Lobo RA
    Am J Med; 2001 Dec; 111(8):602-6. PubMed ID: 11755502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of clinical and laboratory characteristics of cases with polycystic ovarian syndrome based on Rotterdam's criteria and women whose only clinical signs are oligo/anovulation or hirsutism.
    Hassa H; Tanir HM; Yildiz Z
    Arch Gynecol Obstet; 2006 Jul; 274(4):227-32. PubMed ID: 16691383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do hyperandrogenic women with normal menses have polycystic ovary syndrome?
    Carmina E; Lobo RA
    Fertil Steril; 1999 Feb; 71(2):319-22. PubMed ID: 9988405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.